Sei Investments Co. increased its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 7.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 197,806 shares of the biopharmaceutical company's stock after purchasing an additional 14,379 shares during the period. Sei Investments Co. owned 0.19% of Intra-Cellular Therapies worth $16,520,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. True Wealth Design LLC purchased a new stake in Intra-Cellular Therapies in the third quarter valued at approximately $32,000. GAMMA Investing LLC raised its position in Intra-Cellular Therapies by 46.3% in the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company's stock valued at $63,000 after purchasing an additional 240 shares during the last quarter. Venturi Wealth Management LLC acquired a new stake in Intra-Cellular Therapies during the 4th quarter worth $96,000. Wilmington Savings Fund Society FSB acquired a new stake in Intra-Cellular Therapies during the 3rd quarter worth $97,000. Finally, Quarry LP grew its position in Intra-Cellular Therapies by 260.0% during the 3rd quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company's stock worth $132,000 after purchasing an additional 1,300 shares during the last quarter. 92.33% of the stock is owned by institutional investors and hedge funds.
Intra-Cellular Therapies Trading Up 0.1 %
Shares of NASDAQ:ITCI traded up $0.08 during midday trading on Monday, hitting $131.89. 1,236,888 shares of the stock were exchanged, compared to its average volume of 1,391,033. The company has a 50 day moving average price of $129.12 and a 200-day moving average price of $99.80. Intra-Cellular Therapies, Inc. has a twelve month low of $64.09 and a twelve month high of $131.92. The stock has a market cap of $14.05 billion, a P/E ratio of -151.59 and a beta of 0.69.
Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last announced its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The company had revenue of $199.22 million for the quarter, compared to analysts' expectations of $205.08 million. On average, equities research analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.
Analyst Ratings Changes
ITCI has been the subject of several recent research reports. Piper Sandler reiterated a "neutral" rating and set a $132.00 target price (up previously from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. StockNews.com assumed coverage on Intra-Cellular Therapies in a research report on Friday. They set a "hold" rating for the company. Leerink Partnrs lowered Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Needham & Company LLC restated a "hold" rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Finally, Baird R W lowered shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 13th. Ten investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Intra-Cellular Therapies has an average rating of "Hold" and a consensus target price of $106.08.
Get Our Latest Research Report on ITCI
About Intra-Cellular Therapies
(
Free Report)
Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
Featured Articles
Before you consider Intra-Cellular Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intra-Cellular Therapies wasn't on the list.
While Intra-Cellular Therapies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
